Diagnosis and management of PUD Ermias (MD). History Abdominal pain (epigatric burn) –Common for...
-
Upload
theodore-johns -
Category
Documents
-
view
219 -
download
0
Transcript of Diagnosis and management of PUD Ermias (MD). History Abdominal pain (epigatric burn) –Common for...
History• Abdominal pain (epigatric burn)
– Common for DU, GU, NUD– 10% present with complications with out antecedent
pain, eg after NSAID– DU – 90min-3hr after meal, past midnight,
- relieve with food, antacids– GU – worse with meal, nausea and weight
loss are common
• Mechanism of pain– Acid induced chemoreceptor activation in duodenum– Enhanced duodenal sensitivity to bile acids and
pepsin– Altered gastro-duodenal motility
History conti…• Alterations in pain may show complications
– Persistent dyspepsia radiating to the back - penetrating ulcer to pancreas
– Sudden onset severe generalized pain – peritonitis due to perforation (6-7%)
– Worsening vomiting with meals – GOO (1-2%)
– Tarry stool, coffee ground vomits - bleeding (15%)
Physical examination
• Epigastric tenderness
• 20 % slightly to the right of the mid line
• In complications– Tachycardia, hypotension– Signs of peritonitis– Succussion splash
DDx
• NUD (functional, essential)
• Proximal GI tumors
• GERD
• Pancreaticobiliary diseases
• Crohn’s disease (gastro-duodenal)
diagnosis
• Empiric tx as NUD (<45 yrs age)• Ba studies
– Single contrast -80%, double contrast 90% sensitivity– See as well defined crater– Negative in <0.5cm ulcer, post op or scars
• Endoscopy– Photography, tissue biopsy, source of blood loss,
detection of small ulcers
• H. pylori• Serum gastrin, gastric acid analysis - ZES
H. Pylori detections– INVASIVE (ENDOSCOPY/BIOPSY REQUIRED)
• Rapid urease – (80–95/95–100) - Simple, false negative with recent use of PPIs, antibiotics, or bismuth compounds
• Histology – (80–90/>95) - Requires pathology processing and staining;
• Culture - Time-consuming, expensive, allows determination of antibiotic susceptibility
– NON-INVASIVE• Serology – (>80/>90) - Inexpensive, convenient; not
useful for early follow-up• Urea breath test – (>90/>90) - Simple, rapid; useful for
early follow-up; false negatives with recent therapy
– Stool antigen – (>90/>90) - Inexpensive, convenient; promising for eradication
treatment
• Schwartz – “no acid no ulcer” (old dictum)
• New concept– Eradication of H. pylori, – prevention of NSAID induced ds.
Acid neutralizing• Antacids – symptomatic relief
– Al(OH)3 Mg(OH)2– CaCO3, NaHCO3
• H2 receptor blockers – for active ulcer tx with H pylori eradication (4-6wk)– Antiandrogenic, cyt P450 inhibitor, – Elevation of transaminases, cr, prolactin;
pancytopenia
• Proton pump inhibitors– Irreversibly inhibit H+K+ATPase– Rapid onset and prolonged half life– Hypergastrinemia, carcinoid tumors (in animals),
hypochlorhydria (interfere with drug absorption)
Cytoprotective agents
• Sucralfate– Complex sucrose salt of Al(OH)3 and sulfate– Forms viscous paste in the stomach – Gives physicochemical barrier from further tissue
injury– Induce trophic effect on growth factors– Stimulate mucous and bicarbonate secretion– Enhance prostaglandin secretion– SE – constipation, neurotoxicity (Al) in renal
failure
• Bismuth preparations (colloidal bismuth subcitrate, subsalicylate)
– Anti H pylori effect– Mech. for ulcer not clear– Prostaglandin analogues – misoprostal – Enhance mucous bicarbonate secretion, stimulate
mucosal blood flow, decrease mucosal cell turn over
– Se – diarrhea, uterine bleeding and contraction– 200ug QID
Therapy of H pylori• Dramatic decrease in ulcer recurrence• GU 59% - 4%• DU 67% - 6%• Aim of initial eradication – 85-90%• Efficacy, pt tolerance, resistance pattern,
cost• dual tx not recommended < 80% eradication• Unnecessary tx – drug resistance• Infection recurrence in 6 mnth is likely from
recrudescence than reinfection
• TRIPLE THERAPY• 1. Bismuth subsalicylate plus
Metronidazole plus Tetracycline
• 2. Ranitidine bismuth citrate plus Tetracycline plus Clarithromycin or metronidazole
• 3. Omeprazole (lansoprazole) plus Clarithromycin plus Metronidazole or Amoxicillin
• QUADRUPLE THERAPY• Omeprazole (lansoprazole)
Bismuth subsalicylateMetronidazoleTetracycline
• 2 tablets qid250 mg qid500 mg qid
• 400 mg bid500 mg bid500 mg bid
• 20 mg bid (30 mg bid)250 or 500 mg bid500 mg bid1 gr bid
• 20 mg (30 mg) daily2 tablets qid250 mg qid500 mg qid
Tx of NSAID related gastric injury
• Stop the injurious agent
• Use acid inhibitory agent (PPI, H2 blocker)
• Prevention – misoprostol, PPI
• Use of COX -2 inhibitors
• Clinical Setting• Active ulcer
– NSAID discontinued– NSAID continued
• Prophylactic therapy
• H. pylori infection
• Recommendation
• H2 blocker or PPIPPI
• MisoprostolPPISelective COX-2 inhibitor
• Eradication if active ulcer or a past history of peptic ulcer disease
GU vs DU• GU (body, fundal) – likely to be malignant• Repeat endoscopy and biopsy at 8-12 wk• Non healing DU (8wk), GU (12wk) – refractory• Causes:
– Poor compliance– NSAID use– Cigarette smoking– Malignancy– Gastric hyper secretary state (ZES)– Ischemia, Crohn’s ds, Amyloidosis, Sarcoidosis,
Lymphoma, Eosinophilic gastroenteritis, CMV infection, Tuberculosis, syphilis
surgery
• Elective and emergency• Medically refractory ulcer and complicated
ulcers (bleeding, perforation and GOO)• Surgical mx decreased with increased
endoscopic interventions• Procedures:
– 1. vagotomy with drainage– 2. highly selective vagotomy– 3. vagotomy with antrectomy